BIOSPLICE Trademark

Trademark Overview

On Wednesday, July 28, 2021, a trademark application was filed for BIOSPLICE with the United States Patent and Trademark Office. The USPTO has given the BIOSPLICE trademark a serial number of 90852803. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Wednesday, February 25, 2026. This trademark is owned by Biosplice Therapeutics, Inc.. The BIOSPLICE trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for treatment of oncological conditions, osteoarthritis, and degenerative diseases and condition

Research and development in the pharmaceutical and biotechnology fields
biosplice

General Information

Serial Number90852803
Word MarkBIOSPLICE
Filing DateWednesday, July 28, 2021
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateWednesday, February 25, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 15, 2025

Trademark Statements

Goods and ServicesPharmaceutical preparations for treatment of oncological conditions, osteoarthritis, and degenerative diseases and condition
Goods and ServicesResearch and development in the pharmaceutical and biotechnology fields
Description of MarkThe mark consists of the word BIOSPLICE with a slash through the letter S.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, September 25, 2021
Primary Code005
First Use Anywhere DateFriday, April 30, 2021
First Use In Commerce DateFriday, April 30, 2021
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, September 25, 2021
Primary Code042
First Use Anywhere DateFriday, April 30, 2021
First Use In Commerce DateFriday, April 30, 2021

Trademark Owner History

Party NameBiosplice Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
US
Party NameBiosplice Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
US

Trademark Events

Event DateEvent Description
Saturday, July 31, 2021NEW APPLICATION ENTERED
Saturday, September 25, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 28, 2021NOTICE OF DESIGN SEARCH CODE E-MAILED
Monday, April 25, 2022ASSIGNED TO EXAMINER
Wednesday, April 27, 2022NON-FINAL ACTION WRITTEN
Wednesday, April 27, 2022NON-FINAL ACTION E-MAILED
Wednesday, April 27, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, October 27, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 27, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, October 28, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 29, 2022NON-FINAL ACTION WRITTEN
Tuesday, November 29, 2022NON-FINAL ACTION E-MAILED
Tuesday, November 29, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 30, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, May 30, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 30, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 11, 2023FINAL REFUSAL WRITTEN
Tuesday, July 11, 2023FINAL REFUSAL E-MAILED
Tuesday, July 11, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, October 11, 2023EXPARTE APPEAL RECEIVED AT TTAB
Wednesday, October 11, 2023JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, October 11, 2023EX PARTE APPEAL-INSTITUTED
Wednesday, October 11, 2023TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, November 29, 2023NON-FINAL ACTION WRITTEN
Wednesday, November 29, 2023NON-FINAL ACTION E-MAILED
Wednesday, November 29, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, February 29, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, February 29, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 1, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 20, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 25, 2025EXPARTE APPEAL DISMISSED AS MOOT
Tuesday, March 25, 2025EXPARTE APPEAL TERMINATED
Wednesday, April 9, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 15, 2025PUBLISHED FOR OPPOSITION
Tuesday, April 15, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 10, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 19, 2025TEAS STATEMENT OF USE RECEIVED
Tuesday, February 24, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, August 19, 2025USE AMENDMENT FILED
Wednesday, February 25, 2026STATEMENT OF USE PROCESSING COMPLETE

Related Keywords

biosplice pharmaceutical condition research development fields biotechnology diseases degenerative preparations treatment